Skip to content

A Study on the Benefits of Unani Treatments for Pain Relief and Quality of Life in Patients with Knee Osteoarthritis

Effectiveness of Unani Intervention on Quality of Life using WHOQOL-BREF in Chronic Musculoskeletal Disorders: A Retrospective Longitudinal Observational Study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/105626
Enrollment
202
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr Mohamed Nizamuddin K
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Documented presence of pain or dysfunction in the knee joint for a period greater than 3 months. Diagnostic confirmation of knee osteoarthritis through clinical history, physical examination, and imaging (if necessary). Availability of complete inpatient medical records for the duration of the 42-day treatment protocol. Records must contain fully answered WHOQOL-BREF, WOMAC, and VAS assessments specifically at Day 0, Day 14, Day 28, and Day 42.

Exclusion criteria

Exclusion criteria: Medical records of participants with documented systemic illnesses, uncontrolled hypertension, or malignancy. Documented history of psychiatric disorders or mental illness. Records indicating recent major surgery, alcoholism, pregnancy, or lactation. Evidence of concurrent use of other alternative therapies during the admission period. Incomplete case records or missing assessment scores for any of the four designated time points.

Design outcomes

Primary

MeasureTime frame
Measurement of the change in quality-of-life scores using the WHOQOL-BREF in four domains: Physical health, Psychological health, Social relationship, and Environment.Timepoint: Baseline - Day 0, 1st Follow-up - Day 14, 2nd Follow-up - Day 28, and 3rd Follow-up - Day 42

Secondary

MeasureTime frame
Assessment of disease-specific clinical symptoms using the WOMAC index and absolute pain intensity using the Visual Analogue Scale (VAS).Timepoint: Baseline - Day 0, 1st Follow-up - Day 14, 2nd Follow-up - Day 28, and 3rd Follow-up - Day 42

Countries

India

Contacts

Public ContactDr Mubasheera Begum

Government Unani Medical College, Chennai

muskaan.m@gmail.com9841620486

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026